GlassScriptPhysician profile
Star Ye
$15.76
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,380 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,380.12 |
| Education | $169.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $161.84 | 2022-2023 | Tukysa |
| Pfizer INC. | $157.97 | 2023-2025 | |
| Astellas Pharma US INC | $142.52 | 2024-2025 | Padcev |
| Daiichi Sankyo INC. | $133.52 | 2024-2025 | Enhertu, Vanflyta |
| Novartis Pharmaceuticals Corporation | $114.68 | 2024-2025 | |
| Janssen Biotech, INC. | $97.40 | 2024-2025 | Darzalex, Talvey, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $92.58 | 2023-2025 | Enhertu, Tagrisso, Lynparza |
| Glaxosmithkline, LLC. | $73.57 | 2023-2024 | Ojjaara, Jemperli, Zejula |
| E.R. Squibb & Sons, L.L.C. | $55.75 | 2024-2025 | Opdivo, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $54.32 | 2023-2024 | Ninlaro |
| Gilead Sciences, INC. | $46.38 | 2024-2025 | Trodelvy |
| Genentech USA, INC. | $43.55 | 2024-2025 | Tecentriq, Phesgo |
| Lilly USA, LLC | $43.52 | 2024 | Jaypirca, Verzenio |
| Abbvie INC. | $42.50 | 2024-2025 | |
| Array Biopharma INC | $39.17 | 2024-2025 | Braftovi, Tukysa, Mektovi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $35.74 | 2025 | |
| Merck Sharp & Dohme LLC | $34.13 | 2024 | Keytruda |
| Stemline Therapeutics INC. | $30.64 | 2024 | Orserdu |
| Immunogen, INC. | $28.35 | 2023 | Elahere |
| Sobi, INC | $25.61 | 2024 | |
| Beigene USA, INC. | $23.81 | 2023 | Brukinsa |
| Celgene Corporation | $21.92 | 2024 | Reblozyl |
| Deciphera Pharmaceuticals INC. | $21.28 | 2025 | Tgct, Qinlock |
| Acrotech Biopharma INC. | $21.12 | 2024 | Beleodaq |
| Puma Biotechnology, INC. | $20.66 | 2025 | |
| G1 Therapeutics, INC. | $19.05 | 2023 | Cosela |
| Alexion Pharmaceuticals, INC. | $18.17 | 2024 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Star Ye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.